Discover the future of breast cancer therapies

DRG Disease Landscape & Forecast

Key trends in breast cancer treatment:

  • CDK4/6 Inhibitors (Ibrance, Kisqali, Verzenio): Driving robust sales growth in both metastatic and early-stage HR-positive/HER2-negative breast cancer
  • Novel biomarker-driven therapies (Piqray, Truqap, Orserdu): Gaining rapid traction as the market shifts to overcome endocrine resistance
  • HER2-positive disease evolution: The rise of Enhertu as a pivotal therapy, especially in the newly defined HER2-low subgroup
  • Triple-negative breast cancer: Immune checkpoint inhibitors (Keytruda) and TROP2-targeted agents (Trodelvy) moving into earlier treatment lines for greater market impact
Request more information north_east

Complete the form to learn more about the report

The breast cancer – Disease Landscape & Forecast (G7) report delivers comprehensive, data-driven insights across the United States, EU5, and Japan. Backed by expert interviews, cutting-edge epidemiology, and real-time drug pipeline intelligence from Cortellis, this report equips you with the strategic foresight needed to excel in the competitive breast cancer space.

Book a demoperson_pin

Key questions answered:

  • How large are the clinically and commercially relevant drug-treatable breast cancer populations?

  • What is the expected market impact of recent drug approvals, such as Piqray, Orserdu, Truqap, and Enhertu, on the various subpopulations of breast cancer?

  • Which are the most promising agents in the pipeline, and how will they shape the future of this therapy market?

  • What key drivers and constraints will affect the breast cancer therapy market over the forecast period?

 

View the sample deckfile_download
10-year market forecast (2023–2033)

Provides annualized drug-level sales and patient share projections

Emerging therapy analysis

Covers CDK4/6 inhibitors, HER2-targeted agents, TROP2 therapies, and biomarker-driven drugs

The global epidemiology section

Examines incidence, drug-treatable populations, and segmentation by HR/HER2 status, stage, and therapy line

Expert insights

Based on 19 in-depth interviews with thought-leading medical oncologists

Stay ahead with Breast cancer Market Intelligence

Ensure your strategy is informed by the latest trends, forecasts, and competitive insights in breast cancer treatment.

Request more information 3p

What is Disease Landscape & Forecast?

Disease Landscape & Forecast is a premier market intelligence platform, offering:

  • Comprehensive market data including world-class epidemiology, current and emerging therapy insights, and robust drug forecasts

  • Dynamic updates ensuring continuous enhancements to reflect indication-specific developments throughout the year

  • Real-time pipeline intelligence coming directly from Cortellis, with daily updates and interactive figures for in-depth analysis

 

Request more informationnorth_east

Already a Disease Landscape & Forecast client?

Log in login

Expert insights on breast cancer

Built on expert knowledge and rigorous research

  • 19 expert interviews with oncology leaders across the G7 markets

  • Real-time pipeline intelligence powered by Cortellis

  • Robust epidemiological modeling covering key breast cancer subpopulations.


 

Access the brochurefile_download

Complete the form to learn more about the report